Nanobioanálisis
NBA


Hospital Universitario Central de Asturias
Oviedo, EspañaPublications in collaboration with researchers from Hospital Universitario Central de Asturias (153)
2024
-
Cardiac events after allo-HCT in patients with acute myeloid leukemia
Blood Advances, Vol. 8, Núm. 21, pp. 5497-5509
-
Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC
Bone Marrow Transplantation, Vol. 59, Núm. 12, pp. 1694-1703
-
Characterization of the molecular composition and in vitro regenerative capacity of platelet-based bioproducts and related subfractions
Acta Biomaterialia, Vol. 177, pp. 132-147
-
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256
-
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
HemaSphere, Vol. 8, Núm. 12
-
Measurement of GFAP in Nasal Exudate in the Differential Diagnosis between Ischemic Stroke and Intracerebral Hemorrhage
Cerebrovascular Diseases, Vol. 53, Núm. 5, pp. 515-518
-
Nasal exudate for diagnosis of stroke: fundamental studies through iron fractionation, total iron, and targeted protein determinations
Analytical and Bioanalytical Chemistry, Vol. 416, Núm. 24, pp. 5365-5375
-
Next-generation sequencing reveals that miR-16-5p, miR-19a-3p, miR-451a, and miR-25-3p cargo in plasma extracellular vesicles differentiates sedentary young males from athletes
European Journal of Sport Science, Vol. 24, Núm. 6, pp. 766-776
-
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Blood, Vol. 143, Núm. 7, pp. 597-603
-
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
Haematologica, Vol. 109, Núm. 7, pp. 2219-2228
-
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial
Haematologica, Vol. 109, Núm. 12, pp. 4056-4066
2023
-
BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia
Cancer Immunology, Immunotherapy, Vol. 72, Núm. 7, pp. 2529-2539
-
Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy
Molecular Cancer, Vol. 22, Núm. 1
-
Chemo-Immunotherapy: A New Trend in Cancer Treatment
Cancers, Vol. 15, Núm. 11
-
Immunoglobulin-like transcript 2 blockade restores antitumor immune responses in glioblastoma
Cancer Science, Vol. 114, Núm. 1, pp. 48-62
-
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma
Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437
-
Palladium nanoclusters as a label to determine GFAP in human serum from donors with stroke by bimodal detection: inductively coupled plasma-mass spectrometry and linear sweep voltammetry
Microchimica Acta, Vol. 190, Núm. 12
-
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
Haematologica, Vol. 108, Núm. 10, pp. 2753-2763
2022
-
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research
-
Clinical Response After Treatment of Knee Osteoarthritis With a Standardized, Closed-System, Low-Cost Platelet-Rich Plasma Product: 1-Year Outcomes
Orthopaedic Journal of Sports Medicine, Vol. 10, Núm. 3